The activity of the tumor suppressor p53 is induced in response to DNA-damaging agents such as UV and g radiation. Phosphorylation is one of the key regulatory steps for activating p53 function. Recent reports have shown that p53 is phosphorylated at both serines 15 and 392 in response to UV radiation. Phosphorylation at serine 15 prevents the binding of HDM2, a negative regulator of p53. Phosphorylation at serine 392 induces the DNA-binding function of p53. We examined the requirement for phosphorylation at both serines and show that both these modi®cations occur on the same molecule of p53. In vitro assays demonstrate that phosphorylation at either one of these sites is not sucient to yield an active p53. Phosphorylation by DNA-PK, that modi®es serines 15 and 37, inhibits HDM2 binding to p53 but does not induce the DNA-binding activity of p53. Phosphorylation at serine 392, on the other hand, stimulates the DNA-binding ability of p53 but does not make it immune to binding and inhibition by HDM2. Thus, our results demonstrate that multiple sites need to be modi®ed to yield a functional p53. Oncogene (2000) 19, 358 ± 364.
Introduction
P53 is a potent tumor suppressor that controls cell proliferation by acting as a sequence speci®c transcription factor, inducing growth arrest and/or apoptosis when cells are exposed to DNA-damaging agents (Levine, 1997; Aggarwal et al., 1998) . The transcriptional activity of p53 is induced via multiple mechanisms such as, glycosylation (Shaw et al., 1996) , alternate splicing of p53 mRNA (Wu et al., 1994) , binding to p53 antibody pAb421 (Hupp et al., 1992) and by proteolysis (Okorokov et al., 1997) . Recent reports have shown that phosphorylation is a key regulator of p53 activity (for a review, see Giaccia, 1998; Prives, 1998 and references therein) . p53 is a substrate for several kinases such as casein kinase II (CK II; Meek et al., 1990) , DNA-dependent protein kinase (DNA-PK; Lees-Miller et al., 1992) , protein kinase C (Baudier et al., 1992) and mitogen-activated protein kinase (Milne et al., 1994) .
Data from several dierent laboratories have demonstrated that p53 is phosphorylated at several sites in response to DNA-damaging agents such as UV and g radiation. Using site-speci®c p53 phosphoantibodies, p53 has been demonstrated to be phosphorylated at the CK II site (serine 392 in human p53 and serine 389 in murine p53), in response to UV but not g radiation (Kapoor and Lozano, 1998; Lu et al., 1998) . Further, this modi®cation resulted in the induction of the DNA-binding activity of p53 in vivo (Kapoor and Lozano, 1998) .
In vitro phosphorylation of p53 by DNA-PK at serine 15 and serine 37, impairs the ability of MDM2 to inhibit p53-mediated transactivation (Shieh et al., 1997; Mayo et al., 1997) . p53 is phosphorylated at serine 15 in response to both UV and g radiation. Thus modi®ed, p53 is unable to bind MDM2 resulting in the alleviation of MDM2-dependent inhibition of p53 activity (Shieh et al., 1997; Prives, 1998) . Furthermore, serine 15 has been demonstrated to be a substrate for ATM kinase (Bannin et al., 1998; Canman et al., 1998) . Phosphorylation at serine 15 is delayed in AT cells suggesting that after g radiation, ATM signals to p53 through phosphorylation at serine 15 (Siliciano et al., 1997) .
In addition, phosphorylation of p53 at serine 20, in response to DNA damage, is also thought to play a role in modulating the negative regulation of p53 by MDM2. Substitution of serine 20 by alanine results in enhanced binding to MDM2, thus making p53 more prone to MDM2-mediated degradation (Unger et al., 1999; Shieh et al., 1999) .
Recently, Waterman et al. (1998) reported that the DNA-binding activity of p53 is induced by dephosphorylation of serine 376 (a substrate for protein kinase C) by g radiation. Loss of phosphate at this site also correlated with binding of p53 to 14-3-3 proteins (Hermeking et al., 1997; Waterman et al., 1998) . These observations indicate that p53 is modulated by both phosphorylation and dephosphorylation.
Human p53 also undergoes acetylation at lysine 382 and phosphorylation at serine 33 and serine 37 in vivo when cells are exposed to UV or g radiation . Acetylation of p53 at lysine 382 induces the sequence-speci®c DNA binding activity of p53 (Gu et al., 1997; Sakaguchi et al., 1998) . In vivo, the signi®cance of phosphorylation at serine 33 and serine 37 is unknown, but in vitro, amino terminal p53 peptides phosphorylated at serine 33 and/or serine 37 inhibited acetylation of p53 by histone acetyltransferases .
Taken together these studies indicate that p53 is post-translationally modi®ed at several residues when cells are exposed to DNA-damaging agents. However, it is unclear if the same species of p53 is modi®ed at dierent sites or dierent subsets of p53 molecules are phosphorylated/acetylated at speci®c residues upon UV and/or g radiation. Also unknown is whether a single post-translational event is sucient to activate p53.
In this report, we demonstrate for the ®rst time that the same molecules of p53 are modi®ed at both serine 15 and serines 392. While phosphorylation at serine 392 is sucient to activate the DNA-binding function of p53, thus modi®ed p53 is susceptible to inhibition by HDM2. Phosphorylation by DNA-PK (that phosphorylates serines 15 and 37) impairs the ability of HDM2 to inhibit p53 but only partially induces the DNAbinding function of p53. Thus, phosphorylation at multiple serines appears to be required for the activation of p53 upon UV radiation.
Results

Phosphorylation of p53 at serine 392 does not inhibit HDM2-binding
We have shown previously, that p53 is phosphorylated at serine 392 in response to UV radiation and p53, thus modi®ed, is active in DNA-binding assays (Kapoor and Lozano, 1998) . Shieh et al. (1997) demonstrated that p53 is phosphorylated at serine 15 upon UV radiation and this modi®cation alleviates HDM2-mediated suppression of p53 activity. Since alterations of the C-terminus of p53 inhibit HDM2-binding (Kubbutat, 1998), we wanted to determine if phosphorylation at serine 392 also functions to impair the ability of HDM2 to bind and inhibit p53 activity.
We used bacterially expressed human p53 in in vitro phosphorylation assays to determine the aect of phosphorylation by CK II at serine 392 on HDM2 binding. The advantage of using a bacterial expression system is that p53 is not modi®ed at any other site, thus making it possible to study the aect of individual phosphorylation events. CK II-treated or untreated p53 was incubated with GST-tagged HDM2 and the complex was pulled down using glutathione beads and analysed for bound proteins (Figure 1 ). The upper part of the Western blot was probed with SMP14 to detect HDM2 (Figure 1a ) and the lower half was probed to detect p53 (Figure 1b ). HDM2 bound both unphosphorylated (lane 2) and CK II-phosphorylated p53 (lane 3). The Western blot for HDM2 shows multiple bands as seen by others (Shieh et al., 1997) . Lane 1 is a positive control where extracts from cells expressing p53 were analysed. To con®rm that p53 was phosphorylated in these assays, the lower half of the Western blot was autoradiographed (Figure 1c) , to detect the radioactive phosphorus incorporated during the phosphorylation assay. As seen in Figure 1c , at least a subset of p53 pulled down by the HDM2 antibodies, is phosphorylated. These data suggest that phosphorylation of p53 at serine 392 does not inhibit HDM2-binding. However, the possibility that only low levels of p53 were phosphorylated in vitro by CK II, obscure the results.
To overcome this problem, p53 was phosphorylated in vitro with CK II, incubated with HDM2 and the complex was immunoprecipitated with p53 phosphopeptide antibody, Ab389, which is speci®c for p53 phosphorylated at the CK II site (Figure 2 ; Kapoor and Lozano, 1998) . Ab389, co-immunoprecipitated HDM2, as did the control p53 antibody, pAb421 (Figure 2a , lanes 3 and 2, respectively). Figure 2b shows the lower half of the gel that was autoradiographed to detect the radioactive phosphorylated p53 in each lane. Thus, the use of speci®c antibody to phosphorylated p53 indicated that phosphorylation of p53 at serine 392 does not inhibit HDM2 binding to p53.
Next, CK II-phosphorylated p53 was examined for its ability to bind speci®cally the p53 response element in the p21 promoter, in the absence or presence of HDM2 ( Figure 3a ). In this experiment p53 in immunoprecipitated in the presence of radiolabeled DNA and the bound DNA is run on a gel (Kern et al., 1991; Zauberman et al., 1993) . The DNA-binding assays were performed at previously optimized conditions (Kapoor and Lozano, 1998 ) to obtain maximal binding of p53. Phosphorylation via CK II induced the DNA-binding activity of p53 (Figure 3a , compare lanes 2 and 3) as has been demonstrated before (Hupp et al., 1992) . However, if the CK II-phosphorylated p53 was pre-bound to HDM2 before binding to DNA, the DNA-binding activity of p53 was severely diminished (Figure 3a , lane 4). A quantitation of these results is shown in Figure 3b . As a control, HDM2 did not aect the DNA-binding activity of unmodi®ed p53 ( Figure 6b , compare bars 2 and 3). These data show Figure 1 Phosphorylation of p53 at serine 392 does not inhibit HDM2-binding. Bacterially expressed GST-HDM2 and CK IItreated (lane 3) or untreated p53 (lane 2) were used for in vitro binding assays as described in the Materials and methods. The complex was pulled down with glutathione beads and analysed by SDS ± PAGE. The top part of the gel was used for Western blot analysis with SMP14 to visualize HDM2 (a) and the bottom part with pAb421 to detect p53 (b). To verify that p53 was phosphorylated by CK II treatment, the bottom part of the gel was used for autoradiography (c), 24 h after the Western blot was developed to allow for the chemiluminescence to decay. Lane 1 is a positive control where extracts from bacterial cells expressing p53 were run. Lane 4 is a negative control where the ability of p53 to bind glutathione beads in the absence of HDM2 was determined that phosphorylation at serine 392 alone is not sucient to yield an active p53 in the presence of HDM2. The data also suggest that phosphorylation at this site does not play a role in the inhibition of HDM2 binding to p53. p53 may need to be additionally modi®ed to be active in the presence of HDM2. Since p53 has been shown to be phosphorylated at serine 15 upon exposure to UV radiation and this modi®cation inhibits the ability of HDM2 to bind and suppress p53 mediated transactivation, we asked whether the same molecules of p53 are modi®ed at serine 15 and serine 392.
The same p53 molecules are phosphorylated at serine 15 and 389 upon UV-radiation p53 has been shown to be phosphorylated at the CK II site in vivo in response to UV radiation in both RKO cells (at serine 392), a human cell line (Kapoor and Lozano, 1998) and F9 cells (at serine 389), a murine cell line (Levine, 1997) . We treated F9 cells with UV radiation and prepared extracts from these cells at speci®c time points after radiation treatment. The extracts were used for Western blot analyses with dierent antibodies (Figure 4a ). p53 levels were induced at 4 h post-radiation and both antibodies, Ab15 (speci®c for p53 phosphorylated at serine 15; Shieh et al., 1997) and Ab389 (speci®c for human and murine p53 phosphorylated at serine 392/389 respectively; Kapoor and Lozano, 1998) showed reactivity to p53 at that time point. The mdm2 gene, a transcriptional target of p53, also yielded high levels of MDM2 protein, suggesting that p53 is transcriptionally active. A decrease in p53 levels was observed 32 h postradiation with concomitant decrease in p53 reactivity to Ab15 and Ab389. The similar tubulin levels at dierent time points indicated that equivalent amounts of extracts were analysed in each lane.
To determine if the same molecules of p53 are phosphorylated at serines 15 and 389, the extracts from the 12 h time point were pre-cleared with Ab389 to remove all the p53 species that were phosphorylated at serine 389, and the residual extracts were used for Western blot analysis with Ab15. As shown in Figure 4b (top panel), the extracts were depleted of most of the Ab15 reactive species when pre-cleared with Ab389 ( Figure 4b , top panel, compare lanes 1 and 2). Increasing the amount of Ab389 used for immunoprecipitation did not deplete the extracts any further. These data indicate that most of the p53 molecules that are phosphorylated at serine 15, are also modi®ed at serine 392. Figure 4b (bottom panel) shows a control where the . Lane 1 is a negative control where HDM2 was not included in the binding assays. Lane 4 is a positive control where glutathione beads were used to pull down the complexes as in Figure 1 . The complexes were analysed by SDS ± PAGE and the upper part of the gel was used for Western blot analysis with HDM2 antibody, SMP14 (a) and the lower part of the gel was autoradiographed to visualize radioactive p53 (b) Figure 3 HDM2 inhibits the DNA-binding activity of p53 phosphorylated at serine 392. (a) p53 was phosphorylated in vitro by CK II and then bound to HDM2. This complex was used for DNA-binding assays as described before (Kapoor and Lozano, 1998) . Labeled and bound DNA was analysed by 5% nondenaturing polyacrylamide gel followed by autoradiography. Lane 1 shows free probe. CK II-treated (lanes 3 and 4) or untreated p53 (lane 2) was used for its ability to bind the p21 promoter (Reinke and Lozano, 1997) We have demonstrated above that HDM2 binds to CK II-phosphorylated p53 in vitro, and this complex can be immunoprecipitated with Ab389 (Figures 1 and  2 ). However, in vivo, Ab389 was unable to coimmunoprecipitate MDM2 from extracts of UVtreated F9 cells (Figure 4c , lanes 6 ± 10), while a control antibody, pAB421 could (Figure 4c , lanes 1 ± 5). These data provide additional support to our observation that p53, phosphorylated at the CK II site, is additionally modi®ed to inhibit MDM2 interaction. Together with the results in Figure 4b , the data indicate that the additional modi®cation of p53 includes phosphorylation at serine 15.
Dual phosphorylation of p53 with CK II and DNA-PK activates p53 and makes it immune to inhibition of HDM2
Thus far our results demonstrate that phosphorylation at the CK II site alone is insucient to yield an active p53 in the presence of HDM2 and most of the p53 in F9 cells is modi®ed at both serine 15 and serine 389, in response to DNA damage. Next, we wished to directly measure if phosphorylation of p53 at both serines aected the binding to HDM2 and HDM2-mediated repression of p53 activity. We used DNA-PK that phosphorylates p53 at serine 15 and 37 in vitro (LeesMiller et al., 1992) . We performed experiments to determine how phosphorylation with DNA-PK alone or dual phosphorylation with both CK II and DNA-PK aects the activity of p53. We used bacterially expressed p53 for in vitro phosphorylation assays using CK II, DNA-PK, or both kinases in the presence of radioactive phosphate. The extracts were then incubated with bacterially expressed HDM2 and the p53-HDM2 complexes were immunoprecipitated using p53 antibodies. The dierent species of phosphorylated p53 bound HDM2 to dierent levels (Figure 5a ). p53 phosphorylated by DNA-PK alone (lane 3) or doubly phosphorylated to DNA-PK and CK II (lane 4) showed decreased binding to HDM2 as compared to wild type (lane 1) and CK II-treated p53 (lane 2). The lower part of the gel was autoradiographed to detect the extent of phosphorylation of p53 in each case (Figure 5b ). The radioactivity incorporated was quantitated in each case using a phosphoimager and Figure 5c . There was about a 2.5-fold increase in incorporation of phosphate in the presence of both kinases as compared to when one kinase was used for phosphorylation ( Figure 5c , compare bars 2 and 3 with bar 4).
Aliquots of p53 extracts (from Figure 5) were also used for DNA-binding assays (Figure 6a) . Figure 6b shows a quantitation of these results. The DNAbinding activity of unmodi®ed p53 was unaected by the presence of HDM2 (Figure 6b , compare bars 2 and 3). Phosphorylation of p53 by DNA-PK as well as by CK II induced the DNA-binding function of p53, but the latter event resulted in double the activity of that due to phosphorylation by DNA-PK alone (Figure 6b , compare bars 4 and 6). Further, doubly phosphorylated p53 also showed increased DNA-binding to a similar extent as compared to CK II-treated p53 (Figure 6b , compare bars 6 and 8). Moreover, while the DNA-binding activity of CK II-treated p53 was inhibited by the presence of HDM2 (Figure 6b , compare bars 6 and 7), the activity of the DNA-PK treated p53 and that of the doubly phosphorylated p53 was unaected by the presence of HDM2 (Figure 6b , compare bars 4 and 5 and bars 8 and 9).
These results again show that phosphorylation at serine 392 alone is not sucient to yield an active p53 in the presence of HDM2. Phosphorylation by both DNA-PK and CK II impairs the ability of HDM2 to bind and inhibit the activity of p53 and induces the DNA-binding function of p53. Phosphorylation at serine 392 does not inhibit HDM2 binding and phosphorylation by DNA-PK only partially activates the DNA-binding function of p53. Since dual phosphorylation did not induce the DNA-binding function of p53 any more than CK II-treated p53, these data do not support functional synergy between the activities. However, it is possible that phosphorylation at one site facilitates the modi®cation of the other site.
Discussion
The tumor suppressor p53 is activated as a transcription factor following DNA damage and under such circumstances blocks cell cycle progression leading to growth arrest and/or apoptosis (Levine, 1997; Aggarwal, 1998) . Phosphorylation is one of the mechanisms through which p53 is activated when exposed to radiation (Giaccia et al., 1998; Prives, 1998). Specifi- and 7) , or CK II and DNA-PK (lanes 8 and 9) and bound to HDM2 (lanes 3, 5, 7, 9) as before and then used for DNA-binding assays. Lane 1 shows free probe. In lanes 2, 4, 6 and 8, p53 was not bound to HDM2. (b) The bound DNA was quantitated by phosphoimaging and is shown as a bar chart cally, UV-radiation causes phosphorylation of human p53 at serine 15 and serine 392 (389 in mouse). Phosphorylation at serine 15 inhibits HDM2 from binding to p53 (Shieh et al., 1997; Mayo et al., 1997) and that at 392 activates the DNA-binding function of p53 (Kapoor and Lozano, 1998; Lu et al., 1998) .
These phosphorylation events must be studied in the context of the whole p53 molecule. Therefore, we asked whether the two modi®cations occur on the same molecule of p53 or dierent subsets of p53 species are modi®ed at speci®c sites. Our results indicate that both sites get phosphorylated on the same molecules of p53 and that both phosphorylation events occur about the same time in F9 cells after UV radiation. Immunoprecipitation assays using F9 cell extracts, showed that Ab389, that is speci®c for p53 phosphorylated at the CK II site, was unable to co-immunoprecipitate HDM2, unlike a control antibody pAb421, which binds most forms of p53 (Figure 4c) . In this report, we show that both sites need to be phosphorylated to activate p53 in the presence of HDM2. Phosphorylation at serine 392 induces the DNA-binding function of p53 but does not inhibit HDM2-mediated repression of p53 activity. Phosphorylation of p53 by DNA-PK alleviates suppression by HDM2 but yielded a p53 that was only partially active for DNA-binding. Phosphorylation of p53 at both serines resulted in inhibition of HDM2-binding as well as induction of DNA-binding function in vitro. This is the ®rst direct evidence that modi®cations at more than one amino acid is required to yield an active p53.
Con¯icting results have been reported in regards to the aect of HDM2 on the DNA-binding activity of p53. MDM2-p53 complexes could not precipitate a DNA fragment containing the p53 consensus site suggesting that p53, when bound to HDM2 is incapable of binding to DNA (Zauberman et al., 1993) . More recently, Bottger et al. (1997) reported that p53-DNA complexes are supershifted by HDM2. The reason for this controversy could be the use of dierent DNA elements and/or dierent assay conditions. We have performed DNA-binding assays as done by Zauberman et al. (1993) and have arrived at the same conclusion: HDM2 inhibits p53 from binding to DNA.
Phosphorylation of p53 at serines 15 and 392 have been shown to be altered, in two naturally occurring p53 mutants ([Ile 237 ]p53 and [Ala 143 ]p53) in human tumors (Ullrich et al., 1993) . These mutants are defective for p53-mediated transactivation and show decreased phosphorylation at serine 15 and increased phosphorylation at serine 392, providing evidence in support of the requirement for phosphorylation at both the sites to yield a transcriptionally active p53 (Ullrich et al., 1993) .
Although our data do not support functional synergy between the two functions, it is possible that phosphorylation at one site facilitates phosphorylation at other sites by conferring a favourable conformation for the occurrence of the subsequent phosphorylation events. Phosphorylation of serine 392 has been shown to stabilize tetramer formation of p53 and Shieh et al. (1999) have shown that minimal domains required for phosphorylation at serine 15 include the N-terminal transactivation domain and the tetramerization domain of p53. Thus, it is possible that phosphorylation at serine 392 may induce tetramer formation of p53, followed by phosphorylation at serine 15, thus yielding an active p53. We are currently in the process of testing this hypothesis.
Phosphorylation/dephosphorylation is emerging as a vital mechanism for modulating the activity of p53. While serine 15 is phosphorylated upon exposure to both UV and g radiation (Shieh et al., 1997) , serine 20 and 392 are phosphorylated only in response to UV radiation (Shieh et al., 1999; Unger et al., 1999; Kapoor and Lozano, 1998; Lu et al., 1998) . Serine 376 has been shown to be dephosphorylated upon g radiation treatment (Waterman et al., 1998) . p53 is also phosphorylated at serines 33 and 37 and acetylated at lysine 382 in vivo, in response to UV and g-radiation . While acetylation at lysine 382 induced the DNA-binding function of p53, phosphorylation at serine 33 and 37 inhibited acetylation of p53 in vitro (Sakagushi et al., 1998; Gu et al., 1997) .
These observations lead to the tempting speculation that speci®c post-translational events may work in concert to yield an active p53. While a certain set of modi®cations may lead to the induction of p53 activity, such as phosphorylation at serine 15 and serine 392 and acetylation at lysine 382, certain other modifications may inhibit this function. Furthermore, these sets of speci®c modi®cations may occur in a de®nite order that leads to the activation of p53 in response to DNA damage, followed by inactivation upon the removal of stress. The ®rst step towards testing this interesting hypothesis would be to characterize the modi®cations of p53 that may act in concert to achieve a speci®c functional endpoint. In this report we have shown that the same species of p53 is phosphorylated at serine 15 and serine 392 when cells are exposed to UV radiation and both of these modi®cations are required to yield an active p53. It remains to be seen if p53 needs to be additionally modi®ed to result in an active conformation in vivo.
Materials and methods
Constructs, cell lines, antibodies
The human wild type p53 was expressed using IPTG (Sigma) inducible vector pet-15b (Novagen). The mammalian expression construct of human p53 was a gift from A Levine. The dierent mutants were constructed by oligonucleotidedirected mutagenesis and were cloned into this parent vector for expression in mammalian cells. hdm2 construct was obtained from B Vogelstein.
F9 cells and H1299 cells were cultured in DMEM supplemented with 10% fetal bovine serum. Cells were treated with 10 J/m 2 of UV-C radiation using a Stratlinker (Strategene). The p53 antibodies to phospho-serine 15 (Ab15; Shieh et al., 1997) and to phospho-serine 392/389 (Ab389; Kapoor and Lozano, 1998) have been published. HDM2 speci®c antibody SMP14 and the p53 antibody bp53-12 were purchased from Santa Cruz Inc.
In vitro phosphorylation
Extracts from bacterial cells expressing wild type p53 were incubated with CK II (Calbiochem) and/or DNA-PK (Promega) in buer containing 25 mM HEPES (pH 7.9), 50 mM KCl, 10 mM MgCl 2 , 20% glycerol, 1 mM DTT, 16 protease inhibitor cocktail (Boehringer Mannheim) and 10 mg/ml of DNA fragments generated from HpaII digested pBluescript (Strategene). All the reactions were supplemented with 200 mCi/mmol of [g-32 P]ATP (Dupont) and performed at 308C for 10 min.
Immunoprecipitations, Western blot analyses
Immunoprecipitations were performed as described (Kapoor and Lozano, 1998) . The immunoprecipitation complexes were analysed by 10% SDS ± PAGE. 200 mg of crude cell extracts were routinely used for Western blot analysis. Western blots were developed using the enhanced chemiluminiscence kit (Amersham). For pre-clearing assay, the extracts were used for immunoprecipitation with Ab389 and the residual extracts were used for Western blot analysis with Ab15.
DNA-binding assays
DNA-binding assays were performed as described, with minor modi®cations (Kapoor and Lozano, 1998; Wu et al., 1993; Kern et al., 1991) . Brie¯y, the extracts were normalized for protein content and incubated with the 32 P-labeled DNA fragment containing the p21 response element of p53 (Reinke and Lozano, 1997) . The DNA-protein complexes were pulled down with the p53 antibody bp53-12 or Ab389 and the proteins were digested by incubation with 1 mg/ml of proteinase K. The bound DNA was precipitated and analysed by 5% non-denaturing PAGE. The results were quantitated using a Phosphoimager 2 -SI (Molecular Dynamics).
Protein ± protein interaction assays
Bacterial cells expressing the desired protein were lysed in icecold PBS by sonication. Five ml (200 mg) of extracts from bacterial cells expressing GST tagged-HDM2 were mixed with 5 ml (100 mg) of extracts from bacterial cells expressing wild type or mutant p53 and incubated at 308C for 30 min. The protein complexes were pulled down using Glutathione Sepharose 4B beads (Pharmacia Biotech).
